27 augustus 2018: Zie ook dit artikel:
1 mei 2012: Bron: Medscape en N Am J Med Sci. 2011 Nov;3(11):527-30
Avastin - bevacizumab gegeven naast chemo - temodal en bestraling bij hersentumoren - glioblastoom multiforme blijkt de kans op een tweede vorm van hersentumoren de zogenaamde gliosarcomen te bevorderen in plaats van te verminderen. Dit werd gemeld vorig jaar in een case studie. Onderaan in dit artikel staat het abstract van de case studie. Het volledige studierapport daarvan kunt u gratis inzien als u hier klikt inclusief referentielijst.
Secondary gliosarcoma after the treatment of primary glioblastoma multiforme caused by Avastin - bevacizumab
|
N Am J Med Sci. 2011 November; 3(11): 527–530.
doi: 10.4297/najms.2011.3527
|
PMCID: PMC3271412
|
Copyright : © North American Journal of Medical Sciences
Secondary gliosarcoma after the treatment of primary glioblastoma multiforme
1Department of Radiotherapy Oncology, Mohammed V Military Hospital, Rabat, Morocco.
2Department of Pathology, Mohammed V Military Hospital, Rabat, Morocco.
Correspondence to: Khalid Andaloussi-Saghir, No. 2, Wifaq 2, Temara, Morocco. Tel.: 00 212 676975801, Fax: 00 212 537715847, Email: khalidandaloussi@yahoo.fr
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Context:
Gliosarcoma is a rare variant of glioblastoma multiforme containing distinct gliomatous and sarcomatous components. Gliosarcoma comprise 1.8–8% of glioblastoma multiforme and are clinically similar to them, affecting adults in the fourth and sixth decades of life, with a higher proportion found in males. The survival for patients with Gliosarcoma is equally poor as for those with glioblastoma multiforme, and there is a greater propensity for extracranial metastasis in Gliosarcoma. Clinical treatment-related experience reported in the literature is limited, and Gliosarcoma are currently treated in a similar fashion to glioblastoma multiforme, with modalities including tumor resection, postoperative radiation therapy, and chemotherapy. Gliosarcoma can arise secondarily, after conventional adjuvant treatment of high-grade glioma. The current literature on the occurrence of secondary gliosarcoma after glioblastoma multiforme is limited, with only 54 reported cases.
Case Report:
The authors present a 48-year-old Caucasian male who had previously received postoperative combined radiation and temozolomide chemotherapy for glioblastoma multiforme. After a free disease period of 9 months the disease recurs as Gliosarcoma. The patient underwent a Total surgical excision and received chemotherapy with a basis of bevacizumab and irinotecan. The patient died from tumor progression 5 months after gliosarcoma diagnosis.
Conclusion:
The poor survival of patients with secondary gliosarcoma who had previously received combined radiation and temozolomide chemotherapy for glioblastoma multiforme may reflect a unique molecular profile of glioblastoma multiforme that eventually recurs as secondary gliosarcoma. We have to keep in mind the possibility of gliosarcomatous change in the recurrence of malignant glioma. Awareness of this pathological entity will allow more rapid diagnosis and treatment.
References
1. Pardo J, Murcia Mauricio, García Felip, Alvarado Arnaldo. Gliosarcoma: A rare primary CNS tumor.Presentation of two cases. Rep Prac Onco Radiother. 2010;15(4):98–102.
2. Stroebe H. Ueber Entstehung und Bau der Gehirngliome. Beitr Pathol Anat. 1895;18:405–486.
3. Cheong J-H, Kim C-H, Kimand J-M, Oh Y-M. Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: Case report. Clin Neurol Neuroserg. 2010;112(8):701–706.
4. Han SJ, Yang I, Tihan T, Chang SM, Parsa AT. Secondary gliosarcoma: a review of clinical features and pathologic diagnosis. J Neurosurg. 2010;112:26–32. [PubMed]
5. Alatakis S, Stuckey S, Siu K, McLean C. Gliosarcoma with osteosarcomatous differentiation: review of radiological and pathological features. J Clin Neurosci. 2004;11(6):650–656. [PubMed]
6. Lutterbacha J, Guttenberger R, Pagenstecher A. Gliosarcoma: a clinical study. Radiother Oncol. 2001;61:57–64. [PubMed]
7. Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L. Gliosarcomas: analysis of 11 cases do two subtypes exist? J Neuro Oncol. 2005;74:59–63.
8. Cincu R, Juan F, Lázaro M, Luis J, Liesa C, Eiras J. Gliosarcoma: An Uncommon Brain Tumor Pak J Neurol Sci. 2009;4(1):20–22.
9. Han SJ, Yang I, Tihan T, Prados MD, Parsa AT. Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol. 2010;96:313–320. [PMC free article] [PubMed]
10. Chang CH, Horton J, Schoenfeld D, et al. Comparison of post-operative radiotherapy and combined post-operative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas.A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys. 1983;52:997–1007.
11. Mason WP, Maestro RD, Eisenstat D, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14(3):110–117. [PMC free article] [PubMed]
12. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579–584. [PMC free article] [PubMed]
13. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) J Clin Oncol. 2008;26:15S.
14. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–745. [PMC free article] [PubMed]
15. Han SJ, Yang I, Otero JJ, et al. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. J Neurosurg. 2010;112:990–996. [PubMed
Gerelateerde artikelen
- Avastin - Bevacizumab toegevoegd aan chemo (Temozolomide - Temodal) faalt en geeft zelfs slechtere overall overleving op 1 jaar bij een behandeling van een hersentumor Glioblastoma copy 1
- EMA - European Medicines Agency’s Committee bevestigt negatief advies voor gebruik van avastin - bevacizumab bij hersentumoren - Glioblastoma multiforma en trekt toestemming in
- Hersentumoren: Avastin - bevacizumab zorgt uiteindelijk voor meer tumoren - gliosarcomen - bij hersentumoren - glioblastome multiforme in vergelijking met geen Avastin
- Hersentumoren:: Avastin - Bevacizumab samen met chemo zou levensverlengend werken bij nieuw gediagnosteerde operabele hersentumoren (Glioblastoom Multifome) maar zelfs prof. van den Bent bekritiseert studie opzet en spreekt van zinloze studieresultaten.
- Avastin - bevacicumab toegevoegd aan Temodal en irinitocan geeft nagnoeg zelfde resultaten en zelfde toxiciteitspatroon van nieuw gediagnosteerde hersentumoren, glioblastoom multiforme dan zonder avastin
- Hersentumoren: Avastin - Bevacizumab wordt door FDA versneld goedgekeurd voor hersentumoren op basis van niet gerandomiseerde fase II studies en ondanks ontbreken van aantoonbaar bewijs dat Avastin - Bevacizumab ook zou werken bij hersentumoren.
- Hersentumoren Avastin - bevacizumab als aanvullende behandeling voor een recidief van een hersentumor - glioblastoma multiforme vergroot significant het risico op secundaire gliosarcoma
Plaats een reactie ...
Reageer op "Hersentumoren: Avastin - bevacizumab zorgt uiteindelijk voor meer tumoren - gliosarcomen - bij hersentumoren - glioblastome multiforme in vergelijking met geen Avastin"